Approval study DESTINY-Breast04 convinces in new category trastuzumab-deruxtecan: First targeted therapy for metastatic HER2-low breast cancer

被引：0
|
作者：
Fessler, Beate
机构：
来源：
BREAST CARE | 2023年 / 18卷 / 02期
关键词：
D O I：
10.1159/000530539
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: a plain language summary of the DESTINY-Breast04 study
    Modi, Shanu
    FUTURE ONCOLOGY, 2025, 21 (04) : 367 - 380
  • [2] New approval: Trastuzumab-deruxtecan for metastatic breast cancer HER2+
    Minot-This, Marie-Sophie
    Bellesoeur, Audrey
    BULLETIN DU CANCER, 2021, 108 (09) : 783 - 784
  • [3] Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04
    Zhan, Mei
    Huang, Zijia
    Xu, Ting
    Xu, Xinyi
    Zheng, Hanrui
    Wu, Fengbo
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [4] Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptorepositive metastatic breast cancer in DESTINY-Breast04
    Ueno, N. T.
    Niikura, N.
    Yamashita, T.
    Jacot, W.
    Cameron, D. A.
    Tsurutani, J.
    Sohn, J.
    Tokunaga, E.
    Vidal Losada, M. J.
    Park, Y. H.
    Lee, K. S.
    Chae, Y. S.
    Prat, A.
    Suto, F.
    Kuwahara, Y.
    Boran, A. D.
    Kobayashi, M.
    Kumar, V.
    Aguilar, C. Orbegoso
    Modi, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S401 - S402
  • [5] Trastuzumab deruxtecan vs treatment of physician's choice in patients with HER2-low unresectable and/or metastatic breast cancer: Subgroup analyses from DESTINY-Breast04
    Harbeck, Nadia
    Modi, Shanu
    Jacot, William
    Yamashita, Toshinari
    Sohn, Joo Hyuk
    Vidal, Maria
    Tsurutani, Junji
    Ueno, Naoto T.
    Prat, Aleix
    Niikura, Naoki
    Xu, Binghe
    Rugo, Hope
    Papazisis, Konstantinos
    Cortes, Javier
    Krop, Ian
    Gambhire, Dhiraj
    Yung, Lotus
    Wang, Yibin
    Singh, Jasmeet
    Cameron, David
    CANCER RESEARCH, 2023, 83 (05)
  • [6] Determination of HER2-Low Status in Tumors of Patients With Unresectable and/or Metastatic Breast Cancer in DESTINY-Breast04
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 8 - 9
  • [7] Determination of HER2-low status in tumors of patients with unresectable and/or metastatic breast cancer in DESTINY-Breast04
    Prat, Aleix
    Modi, Shanu
    Tsurutani, Junji
    Cameron, David
    Harbeck, Nadia
    Garrido, Charo
    Karnoub, Maha
    Hsu, Ching
    Feng, Wenquin
    Yung, Lotus
    Wang, Yibin
    Gambhire, Dhiraj
    Ford, Shirin K.
    Vitazka, Patrik
    Ueno, Naoto T.
    CANCER RESEARCH, 2023, 83 (05)
  • [8] Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study
    Yamashita, Toshinari
    Sohn, Joo Hyuk
    Tokunaga, Eriko
    Niikura, Naoki
    Park, Yeon Hee
    Lee, Keun Seok
    Chae, Yee Soo
    Xu, Binghe
    Wang, Xiaojia
    Im, Seock-Ah
    Li, Wei
    Lu, Yen-Shen
    Aguilar, Cecilia Orbegoso
    Nishijima, Soichiro
    Nishiyama, Yuji
    Sugihara, Masahiro
    Modi, Shanu
    Tsurutani, Junji
    BREAST CANCER, 2024, 31 (05) : 858 - 868
  • [9] The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer
    Schlam, Ilana
    Tolaney, Sara M.
    Tarantino, Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (11) : 1059 - 1066
  • [10] Trastuzumab Deruxtecan in HER2-Low Breast Cancer
    Ferhanoglu, Burhan
    Atesoglu, Elif Birtas
    Ozbalak, Murat
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (12) : 1147 - 1147
12345